COMMUNIQUÉS West-GlobeNewswire

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
03/07/2025
DELRAY BEACH, Fla., July 03, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds ® ”) (NASDAQ: PETS) received on July 2, 2025, an expected notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating [...]
Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
03/07/2025
Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
AAMI Aligns With National Academy of Medicine AI Code of Conduct
03/07/2025
AI Code of Conduct’s six core principles key to ensuring the safe and effective use of AI technologies Arlington, VA, July 03, 2025 (GLOBE NEWSWIRE) -- The Association for the Advancement of Medical Instrumentation ( [...]
Zelluna ASA - Grant of Share Options under Long-Term Incentive Program
03/07/2025
Oslo, 3 July 2025: On the basis of the approval by the General Meeting on 29 April 2025 to authorize the Board of Directors of Zelluna ASA (the ‘Company’, OSE ticker “ZLNA”) to grant new shares to employees and board [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/07/2025
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/07/2025
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of [...]
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies
03/07/2025
Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGAP®-Verify discovery platform OBT receives milestone payment associated [...]
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team
03/07/2025
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team Egham, UK – 03 July 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company [...]
HUTCHMED to Announce 2025 Half-Year Financial Results
03/07/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, [...]
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
03/07/2025
The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA 1 Safety in GCA patients was consistent with known safety profile of Cosentyx® ( [...]
Nixol Weight Loss Capsules UK & IE Officially Launched- Exploring the Science Behind its Weight Loss Tablets Promises
03/07/2025
New York City, NY, July 03, 2025 (GLOBE NEWSWIRE) -- In 2025, Nixol, a plant-based dietary supplement, made its debut in the United Kingdom and Ireland, marking a significant entry into the wellness supplement market. [...]
Theratechnologies conclut un accord définitif en vue de son acquisition par CB Biotechnology, un membre du même groupe que Future Pak
03/07/2025
Une offre de 3,01 $ US en espèces plus un droit conditionnel à la valeur représentant des paiements supplémentaires totaux potentiels pouvant atteindre 1,19 $ US par action La contrepartie initiale et la contrepartie [...]
Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
03/07/2025
Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per share Upfront and total potential cash consideration represent respectively a 126% and 216% [...]
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
02/07/2025
4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 2027 4FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns with focused pipeline [...]
Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market
02/07/2025
PASADENA, CALIF, July 02, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a private placement with [...]
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
02/07/2025
Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis GAITHERSBURG, Md., July 02, 2025 (GLOBE [...]
Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry
02/07/2025
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first patient in the [...]
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
02/07/2025
FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the [...]
Oragenics Completes Approximately $16.5 Million Offering
02/07/2025
Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injury SARASOTA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical- [...]

Pages